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TAZ is a WW domain containing a transcription coactivator that modulates mesenchymal differentiation
and development of multiple organs. In this study, we show that TAZ is phosphorylated by the Lats tumor
suppressor kinase, a key component of the Hippo pathway, whose alterations result in organ and tissue
hypertrophy in Drosophila and contribute to tumorigenesis in humans. Lats phosphorylates TAZ on several
serine residues in the conserved HXRXXS motif and creates 14-3-3 binding sites, leading to cytoplasmic
retention and functional inactivation of TAZ. Ectopic expression of TAZ stimulates cell proliferation, reduces
cell contact inhibition, and promotes epithelial-mesenchymal transition (EMT). Elimination of the Lats
phosphorylation sites results in a constitutively active TAZ, enhancing the activity of TAZ in promoting cell
proliferation and EMT. Our results elucidate a molecular mechanism for TAZ regulation and indicate a
potential function of TAZ as an important target of the Hippo pathway in regulating cell proliferation
tumorigenesis.
Genetic screens of flies over the past several years have delin-
eated the new Hippo-signaling pathway, which controls tissue and
organ size by regulating cell proliferation and apoptosis (23, 26).
Two previously defined components of this pathway, Hippo
(Hpo) and Warts (Wts), code for the serine/threonine kinases that
belong to the Ste20 and the nuclear Dbf2-related protein kinase
families, respectively (4, 30). Hpo complexes have the regulatory
subunit Salvador (Sav) and activate Wts by phosphorylation,
whereas Wts associates with its activating subunit Mats (mob as
tumor suppressor) and phosphorylates Yorkie (Yki), which is a
transcription coactivator (12, 36). High Yki activity induces the
expression of cyclinE and Diap1 in Drosophila melanogaster, lead-
ing to increased cell proliferation and decreased apoptosis (8, 32).
Merlin (Mer) and Expanded (Ex) are two cytoskeleton-associated
proteins acting upstream of Hpo (8, 19). Recently, the tumor
suppressor Fat, a cell surface protocadherin, has been added to
the Hpo pathway, indicating a possible role for the Hippo path-
way in cell contact inhibition (2, 27, 37). How the Hippo pathway
regulates cytoskeleton organization and cell contact inhibition is
not known.
Components of the Hippo pathway are found in all eu-
karyotes and are highly conserved in multiple cellular organ-
isms. For example, Mst and Lats are human homologues of the
Drosophila Hpo and Wts, respectively (7). The mammalian
yes-associated protein (YAP) shows high sequence similarity
with Yki and can functionally rescue the Drosophila yki muta-
tion (7). These results suggest that the Hippo pathway is likely
to function in mammals as well. A recent study has shown that
YAP is indeed inhibited by the Hippo pathway in mammalian
cells (6). Accumulating evidence supports an important role
for this pathway in human cancer. YAP has recently been
demonstrated to be the oncogene in human amplicon 11q22
(22). Moreover, Mer is encoded by the neurofibromatosis type
2 (NF2) tumor suppressor (19). Other components of the
Hippo pathway, such as Sav, Mats, Lats1/Lats2, and Wts, have
also been implicated in human cancer (14, 28, 29, 31).
The transcriptional coactivator with PDZ binding motif
(TAZ), first reported as a 14-3-3 binding protein (13) and
independently as a binding target of the oncogenic mouse
polyomavirus T (tumor) antigens (34), is closely related to
YAP. Both proteins share approximately 50% sequence iden-
tity, with a similar topology, containing two central WW do-
mains and a C-terminal transactivation domain. TAZ has been
reported to bind with a variety of transcription factors such as
the RUNX family, TEAD, thyroid TF1 (TTF-1), TBX5, paired
box homeotic gene 3 (Pax3), and PPAR (3, 9, 10, 16, 20, 21,
24). Consistent with these diverse interactions, the TAZ func-
tion has been linked with the development of limb, heart, bone,
muscle, fat, and lung tissues (9, 10, 16, 20, 24). TAZ has also
been implicated in mesenchymal stem cell differentiation (9).
However, whether TAZ plays a role in cancer is unclear. Ad-
ditionally, it has also been reported that TAZ is a phospho-
protein, and phosphorylation likely regulates TAZ interaction
with 14-3-3 and subcellular localization (13). The responsive
TAZ kinase(s) has yet to be clearly defined.
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In this study, we demonstrate that TAZ is regulated by the
Hippo pathway. TAZ is inhibited by the Lats kinase via phos-
phorylation of the conserved HXRXXS motif. This phosphor-
ylation creates the 14-3-3 binding site in TAZ, leading to the
sequestration of TAZ from the cell nucleus. We also show that
TAZ promotes cell proliferation and induces epithelial-mes-
enchymal transition (EMT), indicating a potential role for
TAZ in tumorigenesis. Phosphorylation and inhibition of TAZ
may represent a critical consequence of the Hippo pathway in
tumor suppression.
MATERIALS AND METHODS
Cell culture and transfection. 293T, HeLa, and BOSC cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented with
10% fetal calf serum (HyClone), 100 U/ml penicillin, and streptomycin (Gibco).
MCF10A cells were maintained in DMEM/F-12 medium (Invitrogen) supple-
mented with 5% horse serum (Invitrogen), 20 ng/ml epidermal growth factor, 0.5
g/ml hydrocortisone, 10 g/ml insulin, 100 ng/ml cholera toxin, 100 U/ml pen-
icillin, and streptomycin (Gibco). Cell transfection was performed using Lipo-
fectamine 2000 (Invitrogen) or calcium phosphate methods. Cells were harvested
at 24 h posttransfection for protein analysis or luciferase activity assay.
To establish stable TAZ-expressing cells, pBabe-TAZ retroviruses were gen-
erated and used to infect MCF10A cells. Stable pools were selected with puro-
mycin for 5 days. TAZ stable pool cells were seeded in 6-well plates with 1  105
cells/well in triplicates. Cell growth was counted every day for 7 days.
Immunofluorescence staining. Cells were fixed in 4% paraformaldehyde for
1 h, followed by washing in phosphate-buffered saline (PBS). The endogenous
peroxidase activity was inactivated in a solution containing 3% hydrogen perox-
ide (H2O2) in methanol. The following detection and visualization procedures
were performed according to the manufacturer’s protocols. Negative control
slides were performed without primary antibody. Control slides known to be
positive for each antibody were incorporated. For double-fluorescence staining,
pretreated sections were first blocked with goat serum at a 1:20 dilution and 1%
bovine serum albumin blocking and then incubated with mouse antibody hem-
agglutinin (HA) (catalog no. sc-9353; Santa Cruz Biotechnology) and rabbit
antibody Flag (product no. F3165; Sigma) at 4°C overnight, followed by fluores-
cein isothiocyanate (FITC)-conjugated anti-mouse 488 (catalog no. A11001;
Invitrogen) and anti-rabbit 594 (catalog no. A11012; Invitrogen) secondary an-
tibody.
Luciferase activity assay. For the luciferase reporter assay, BOSC cells were
seeded in 24-well plates. A mixture of 5 upstream activating sequence (UAS)-
luciferase reporter, Renilla, and the indicated plasmids were cotransfected.
Twenty-four hours after cells were transfected, they were lysed, and luciferase
activity was measured using a dual-luciferase reporter assay system (catalog no.
E1960; Promega) following the manufacturer’s instructions. The luciferase ac-
tivity was measured by a luminometer (model TD-20/20). Transfection efficiency
was normalized to thymidine kinase-driven Renilla luciferase activity.
BrdU labeling and flow cytometric analysis. For cell cycle analysis, cells were
cultured to the desired confluence and then labeled with 5-bromo-2-deoxyuri-
dine (BrdU) and analyzed by flow cytometry, using an FITC BrdU flow kit
obtained from BD Biosciences (San Jose, CA), following the manufacturer’s
instructions. Briefly, cells were pulse-labeled with 15 M BrdU in the culture
medium for 30 min. After cells underwent trypsinization and a PBS wash, they
were fixed and permeabilized. After DNase treatment, cells were stained with
FITC-conjugated anti-BrdU antibody. Total DNA was stained by propidium
iodide. Data were collected with a BD FACSCalibur and analyzed with Cell
Quest Pro software.
Immunoprecipitation and kinase assay. For the Lats2 and Mst2 kinase assays,
293T cells were transfected with HA-Lats2 or Flag-Mst2. Thirty-six hours post-
transfection, cells were lysed with lysis buffer (50 mM HEPES [pH 7.5], 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 50 mM NaF, 1.5 mM Na3VO4, protease inhib-
itor cocktail [Roche], 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride
[PMSF]) and immunoprecipitated with anti-HA or anti-Flag antibodies. The
immunoprecipitates were washed three times with lysis buffer, followed by a
single wash with wash buffer (40 mM HEPES, 200 mM NaCl) and a single wash
with kinase assay buffer (30 mM HEPES, 50 mM potassium acetate, 5 mM
MgCl2). The immunoprecipitated Lats2 or Mst2 was subjected to a kinase assay
in the presence of 500 M cold ATP and 1 g His-TAZ expressed and purified
from Escherichia coli as the substrate. The reaction mixtures were incubated at
25°C for 50 min, terminated with sodium dodecyl sulfate (SDS) sample buffer,
and subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and enhanced
chemiluminescence development.
RNA isolation and real-time PCR. Total RNA was isolated from cultured cells
using Trizol reagent (Invitrogen). cDNA was synthesized by reverse transcription
using oligo(dT) as the primer and proceeded to real-time PCR with gene-specific
primers in the presence of SYBR Premix Ex Taq (catalog no. DRR041A;
TaKaRa). The relative abundance of mRNA was calculated by normalization to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA.
Western blotting analysis. Protein lysates were prepared from transfected
293T, BOSC, MCF10A, and MCF10A TAZ stable pool cells in a buffer contain-
ing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1%
NP-40, 1 mM EDTA, 1 mM PMSF, 25 mM NaF, and cocktail protease inhibitors
(Roche). Tissue lysate (40 g) was resolved by SDS-PAGE, followed by Western
blotting analysis using HA (catalog no. A00168; GenScript), FLAG (catalog
no. A00170; GenScript), MYC (catalog no. A00172; GenScript), E-cadherin
monoclonal antibody (MAb) (catalog no. 610405; BD), N-cadherin MAb (cata-
log no. 610920; BD), vimentin MAb (catalog no. 550513, BD), occludin (catalog
nos. H-279 and SC-5562; Santa Cruz Biotechnology), fibronectin MAb (catalog
no. F0916; Sigma), pYAP(S127) (catalog no. 4911S; Cell Signaling), and beta-
actin (13E5 [catalog no. 4970]; Cell Signaling).
For immunoprecipitation experiments, 500 g of cell lysate was incubated for
12 h at 4°C with anti-FLAG M2-agarose (catalog no. A2220; Sigma), c-MYC
(9E10) agarose conjugate beads (catalog no. sc-40 AC; Santa Cruz Biotechnol-
ogy) or HA antibody (F-7 [catalog no. sc-7392]; Santa Cruz Biotechnology) plus
25 g protein A agarose beads (catalog no. 16-125; Upstate). Beads were washed
three times with lysis buffer and centrifuged for 5 min at 5,000  g between each
wash. Protein was eluted from beads with 50 l of Laemmli sample buffer
(Bio-Rad). Lysates were resolved on 8 to 10% SDS-PAGE gels and transferred
onto nitrocellulose (Bio-Rad) for Western blotting.
Wound-healing assay. Monolayer cells were wounded with a sterile plastic tip.
Cell migration was observed 16 h later by microscopy.
Matrigel assay. A Matrigel assay was performed as reported previously, with
minor modifications (5). Briefly, the well of a chamber was precoated with 100%
Matrigel (BD Pharmingen). Cells (5,000) were plated onto the Matrigel bed and
cultured with mammary epithelial cell growth medium supplemented with hy-
drocortisone, insulin, epidermal growth factor, fetal bovine serum, and 2%
Matrigel. Acinar formation was monitored by microscopy. For immunostaining,
the acini were fixed with formalin, paraffin embedded, and stained with antibod-
ies to PH3, a polyclonal antibody against mitosis-specific phosphorylated histone
H3 (Upstate Biotechnology).
RESULTS
Transcription activity of TAZ is inhibited by the Hippo
pathway. The TAZ transcription coactivator is closely related to
YAP, which is the mammalian ortholog of the Drosophila Yki, a
key component in the Hippo pathway (12). However, whether
TAZ is regulated by the Hippo pathway has not been reported.
TAZ has been implicated in the differentiation of mesenchymal
tissue to bone and organ development. However, the molecular
regulation of TAZ is largely unknown. We investigated whether
the Hippo pathway regulates TAZ and found that the expression
of Mst2 or Lats2 caused an obvious TAZ mobility shift (Fig. 1A),
indicating that Mst2 and Lats2 may promote TAZ phosphoryla-
tion. Sav and Mob are regulatory subunits for the Mst2 and Lats2
kinases, respectively. Interestingly, the coexpression of Sav and
Mob enhanced the effect of Mst2 and Lats2 on the mobility shift
of TAZ (Fig. 1A). Moreover, the coexpression of both Mst2 and
Lats2 led to an even more dramatic mobility shift of TAZ (Fig.
1A). The coexpression of kinase-dead mutants of Mst2 and Lats2
failed to induce a TAZ mobility shift, suggesting kinase activity is
required (Fig. 1A). The mobility of TAZ induced by Mst2 and
Lats2 can be reversed by treatment with lambda phosphatase
(Fig. 2B). These results show that Mst2 and Lats2 induce TAZ
phosphorylation.
Next, we examined the functional effect of the Hippo path-
way components on TAZ, which has been reported to interact
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with and stimulate several transcription factors, including the
TEAD family transcription factor. We utilized a TAZ tran-
scription reporter system in which a luciferase was under the
control of five Gal4 binding elements. The expression of Gal4-
TEAD4 provided basal luciferase activity; however, the coex-
pression of TAZ dramatically increased the reporter activity
(Fig. 1B). We examined the effect that the Hippo pathway
components had on TAZ reporter activity. We found that the
individual expression of Mst2 and of Lats2 inhibited TAZ
activity and that the combination of both resulted in a further
decrease of TAZ activity (Fig. 1B). In accord with the obser-
vation of TAZ phosphorylation, the coexpression of Sav or
Mob with Mst2 and Lats2 further inhibited TAZ activity. An
even more dramatic inhibition was observed by the combina-
tion of all five Hippo pathway components (Fig. 1B). These
results indicate that the Hippo pathway inhibits TAZ and links
the phosphorylation of TAZ by Mst2 and Lats2 with its func-
tional inhibition.
FIG. 1. The transcription coactivator activity of TAZ is inhibited by the Hippo pathway. (A) The cotransfection of Mst2 and Lats2 decreases
TAZ electrophoretic mobility. Flag-TAZ was cotransfected with the indicated plasmids into BOSC cells (a cell line derived from HEK 293), and
Western blotting was employed to examine TAZ mobility. (B) TAZ activity is repressed by Mst2 and Lats2. The 5 GAL4 UAS-luciferase reporter
and GAL4-TEAD4 were transfected into BOCS cells, with the indicated plasmids. Renilla luciferase plasmid was also cotransfected as an internal
control. Firefly luciferase activity was measured and normalized to Renilla luciferase activity. Data are representative of three independent
experiments. The coexpression of the Hippo pathway components Mst2, Sav, Lats2, and Mob inhibited TAZ activity. (C) TAZ activity is inhibited
by human Ex and Mer. The experiments shown are similar to those shown in panel B. Both Ex and Mer cause a significant inhibition of the TAZ
reporter. (D) Kinase activity is required for Mst2 and Lats2 to inhibit TAZ. Increasing amounts of wild-type Lats2 (upper panel) or Mst2 (lower
panel) were cotransfected with the TAZ reporter. Both Lats2 and Mst2 show a dose-dependent inhibition of the TAZ reporter. In contrast, the
kinase-inactive mutants (K/R) of both Lats2 and Mst2 cannot inhibit the TAZ reporter.
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We also assessed the effect of Mer and Ex on TAZ activity.
It has been suggested that both Mer and Ex function upstream
of Mst2. Cotransfection of Mer or Ex resulted in a modest but
reproducible repression of TAZ activity (Fig. 1C). The weak
effect of Mer and Ex could be due to the fact that components
acting between Mer/Ex and Lats is limiting in this cell line. We
tested the requirement of Mst2 and Lats2 kinase activity for
their inhibition of TAZ. Both wild-type Mst2 and Lats2 dis-
played a dose-dependent inhibition of the TAZ reporter, while
the kinase-dead mutants were completely inactive and had no
inhibitory effect on TAZ reporter (Fig. 1D). Together, our
data demonstrate that TAZ is inhibited by the Hippo pathway,
probably via a phosphorylation-dependent mechanism.
Lats2 inhibits TAZ activity by phosphorylating the
HXRXXS motif. Lats2 and Wts belong to the nuclear Dbf2-
related family of protein kinases. Biochemical studies of the
Saccharomyces cerevisiae Dbf2 kinase indicate that it recog-
nizes the RXXS motif in its substrates (15). In search of such
consensus, we noticed that TAZ contains four HXRXXS mo-
tifs (Fig. 2A). It is worth noting that the His residue at the 5
position was also presented in the synthetic peptide used by
Mah et al. (15). Therefore, we determined whether the four
HXRXXS motifs in TAZ represent the putative Lats2 phos-
phorylation sites.
We generated a series of TAZ mutants by replacing individ-
ual serine residues in the HXRXXS motifs with alanine. Mst2
and Lats2 cotransfection could induce a mobility shift of all
single-point TAZ mutants (TAZS89A, TAZS66A, TAZS117A,
and TAZS311A), indicating that Lats2 phosphorylates on mul-
tiple sites (Fig. 2B). Lambda phosphatase treatment abolished
the mobility shift of TAZ caused by Mst2 and Lats2, confirm-
ing that this mobility shift was indeed due to phosphorylation
(Fig. 2B). In contrast, TAZ4SA, which had all four serine res-
idues in the HXRXXS motif replaced with alanine, was resis-
tant to the mobility shift caused by Mst2 and Lats2. These
results indicate that some or all of the four serine sites in the
HXRXXS motifs were phosphorylated by Lats2.
We examined the functional significance of TAZ phosphor-
ylation by using the TAZ reporter assay described in the leg-
end to Fig. 1B. As shown, the wild-type TAZ was efficiently
inhibited by the coexpression of Mst2 and Lats2. Among all
single-point mutations, however, the TAZS89A mutant showed
a significant resistance to inhibition by Mst2 and Lats2, while
TAZS311A also displayed partial resistance to inhibition (Fig.
FIG. 2. Lats2 inhibits the function of TAZ via phosphorylation. (A) TAZ contains four HXRXXS motifs as the putative Lats phosphorylation
sites. The yeast Dbf2 optimal target sequence was aligned with the four HXRXXS motifs of human TAZ. (B) The putative HXRXXS motifs in
TAZ are required for a mobility shift by Lats2 and Mst2. The wild type (WT) or the mutant Flag-TAZ was cotransfected with HA-Mst2 and
HA-Last2, as indicated. The TAZ mobility shift was examined by Western blotting. The 4SA mutation denotes the quadruple mutation of all four
putative phosphorylation sites. As indicated, treatment with lambda phosphatase abolished the mobility shift by Lats2 and Mst2 cotransfection,
indicating that the mobility shift is due to phosphorylation. (C) The S89A and S4A TAZ phosphorylation mutants are resistant to inhibition by
Mst2 and Lats2. The S89A mutation and the phosphorylation mimic S89D mutant made no difference in the inhibition by Mst2 and Lats2. The
reporter assay was performed similar to that shown in panel A. The inhibition change (n-fold) for each mutant is shown at the top of this panel.
(D) The coexpression of Mst2 and Lats2 increases TAZ Ser89 phosphorylation. Lats2K/R dramatically decreases TAZ Ser89 phosphorylation.
Flag-TAZ was cotransfected with Lats2, Mst2, or kinase-dead Lats2K/R into 293T cells, as indicated. Flag-TAZ was immunoprecipitated, and
phosphorylation of Ser89 was detected by pYAP(Ser127) antibody, which can recognize the Ser89 phosphorylation site because of sequence
conservation. Lambda phosphatase treatment and the TAZS89A mutant abolished the recognition of phosphoTAZ by the anti-phosphoYAP
antibody. This result confirms the specificity of the phosphoYAP antibody. (E) In vitro phosphorylation of TAZ by Lats2. HA-Lats2 or Flag-Mst2
was immunoprecipitated from transfected 293T cells. An in vitro kinase assay was performed using purified His-TAZ as a substrate. Phosphor-
ylation of TAZ was detected by pYAP(S127) antibody. His-TAZ input was shown by Coomassie blue staining. (F) A knockdown of Lats decreases
TAZ Ser89 phosphorylation. HeLa cells cotransfected HA-TAZ with small interfering (siRNA) for Lats1 and Lats2, as indicated. Phosphorylation
and protein levels of TAZ were determined by Western blotting. A knockdown of Lats was verified by quantitative PCR (data not shown).
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2C). Furthermore, the TAZ4SA mutant not only was resistant
to inhibition by Mst2 and Lats2 but also displayed an elevated
basal activity, presumably resulting from an increased resis-
tance to the endogenous TAZ kinases (Fig. 2C). We also
generated an S89D mutant and compared its activity with that
of the wild type and the S89A mutant. We found that the S89D
mutant is active and resistant to inhibition by Lats and Mst,
similar to the S89A mutant (Fig. 2C). These data indicate that
the mutation of Ser89 to aspartate does not mimic the effect of
phosphorylation. Instead, the S89D mutant acts similarly to the
nonphosphorylatable mutant. These data demonstrated that
Lats2 phosphorylates the HXRXXS motifs in TAZ, especially
Ser89 and Ser311, and this phosphorylation inhibits the tran-
scriptional activity of TAZ.
To determine the function of Lats2 in TAZ phosphorylation
in vivo, we examined TAZ Ser89 phosphorylation in culture
cells. Ser89 in TAZ corresponds to Ser127 in YAP (Fig. 2A).
We found that the phosphoYAP(Ser127) antibody could rec-
ognize TAZ. We observed that the coexpression of Lats2 or/
and Mst2 enhanced TAZ Ser89 phosphorylation (Fig. 2D). To
verify the specificity of the phosphoYAP(Ser127) antibody, we
treated the immunoprecipitated TAZ with lambda phos-
phatase and included the expression of the TAZS89A mutant.
Our data showed that the phosphatase treatment completely
abolished the recognition by the phosphoYAP(Ser127) anti-
body and the expression of the TAZS89A mutant leads to the
diminishment of p-TAZ(S89) (Fig. 2D). Interestingly, the
Lats2 kinase-dead mutant (Lats2K/R) coexpression decreased
the TAZ basal phosphorylation significantly below that of the
control, indicating that Lats2K/R functions as a dominant neg-
ative and also suggesting the functional role for endogenous
Lats2 in TAZ phosphorylation.
In order to address whether Lats2 or Mst2 directly phos-
phorylates TAZ, we performed an in vitro kinase assay using
purified His-TAZ protein from bacteria and immunoprecipi-
tated Lats2 or Mst2. We used p-YAP(S127) antibody, which
can recognize the TAZ Ser89 phosphorylation site because of
sequence conservation, to detect Ser89 phosphorylation by
Lats2. As shown in Fig. 2E, Lats2 phosphorylated TAZ wild
type but not TAZS89A or TAZ4SA. In contrast, Mst2 could not
phosphorylate His-TAZ in vitro (Fig. 2E). These data demon-
strate that Lats2 directly phosphorylates TAZ, while Mst2
stimulates TAZ phosphorylation indirectly in vivo, perhaps by
activating Lats2. Therefore, our data suggest a linear model:
Mst  Lats  TAZ. We generated an R86A mutant to deter-
mine the importance of the arginine in TAZ phosphorylation
by Lats2. In vitro kinase assays showed that the R86A mutant
dramatically decreased TAZ Ser89 phosphorylation (Fig. 2E),
indicating that Arg86 was important for TAZ Ser89 phosphor-
ylation by Lats. We further examined the functional role of
endogenous Lats in TAZ phosphorylation by down-regulating
Lats. Lats1 and Lats2 were down-regulated by RNA interfer-
ence, and the phosphorylation of TAZ was determined. The
knockdown of Lats2 caused a significant decrease in the Ser89
phosphorylation of transfected HA-TAZ, while the knock-
down of both Lats1 and Lats2 almost abolished its phosphor-
ylation (Fig. 2F). These results support the functional impor-
tance of endogenous Lats in TAZ phosphorylation.
Phosphorylation regulates TAZ localization and interaction
with 14-3-3. It was previously reported that TAZ phosphory-
lation promotes its cytoplasmic localization (13). We wondered
if this phosphorylation is important for TAZ localization. Fur-
thermore, Ser89 has been implicated in 14-3-3 binding, al-
though the responsible kinase was unknown (10). Our studies
have shown that Lats likely phosphorylates TAZ on Ser89. We
wanted to test whether Mst2 and Lats2 might also regulate
TAZ subcellular localization. We found that the transfected
TAZ was distributed throughout the cell. However, the coex-
pression of Lats2 or Mst2 significantly decreased nuclear TAZ,
resulting in a clear nuclear exclusion of TAZ (Fig. 3A). These
effects depend on the kinase activity, as neither Lats2K/R nor
Mst2K/R caused TAZ nuclear exclusion, indicating that the
effects of Mst2 and Lats2 on TAZ localization is not nonspe-
cific (Fig. 3A). We further tested the phosphorylation-defec-
tive TAZ mutations S89A and 4SA. Our results showed that
Mst2 and Lats2 failed to promote the nuclear exclusion of the
TAZ phosphorylation mutant. We also performed subcellular
fractionation and found that more of the TAZS89A mutant
protein was found in the nuclear fraction than in that of the
wild-type protein (Fig. 3B). These results strongly suggest that
the phosphorylation of TAZ retains it in the cytoplasm. These
data are consistent with the TAZ transcription reporter assay,
where Mst2 and Lats2 inhibit TAZ activity.
TAZ was initially isolated as a 14-3-3 binding protein (13).
The 14-3-3 binding is a mechanism used commonly to promote
the cytoplasmic retention of nuclear proteins, such as Foxo1
(39). We found that the coexpression of both Lats2 and Mst2
strongly increased the interaction between TAZ and 14-3-3ε,
based on coimmunoprecipitation experiments. In contrast, the
TAZS89A and TAZ4SA mutants showed little interaction with
14-3-3ε, and the coexpression of Mst2 and Lats2 did not en-
hance the interaction between the TAZ mutant and the 14-
3-3ε protein (Fig. 3C). Our data indicate that Lats2 promotes
TAZ cytoplasmic localization primarily by stimulating Ser89
phosphorylation and its binding with 14-3-3ε. Together, our
data provide a possible biochemical mechanism, promoting
TAZ’s binding with 14-3-3 and thus cytoplasmic retention, for
the inhibition of TAZ by the Hippo pathway.
TAZ stimulates cell proliferation. YAP is a candidate human
oncogene in the amplicon 11q22 (23). Many components in the
Hippo pathway, including Mer, Lats, and Sav, have been im-
plicated as tumor suppressor genes (14, 19, 28, 29, 31). To
FIG. 3. Phosphorylation increases TAZ cytoplasmic localization and 14-3-3 association. (A) Phosphorylation is important for TAZ nuclear
exclusion caused by Lats2 and Mst2. Flag-TAZ (wild type and S89A and 4SA mutants) was cotransfected with HA-Lats2 or HA-Mst2, as indicated.
Immunofluorescence using anti-Flag antibody (red) and HA antibody (green) was performed. DNA was stained with 4,6-diamidino-2-phenylin-
dole (DAPI) (blue). The merged figures are shown in the lower right corner of each panel. (B) The mutation of Ser89 increases nuclear TAZ.
HA-TAZ and the S89A mutant were cotransfected with Mst2 and Lats2 into HEK293 cells. Cytoplasmic and nuclear fractions were separated and
analyzed by Western blotting. WT, wild type. (C) Flag-TAZ was cotransfected with Myc 14-3-3 and other indicated plasmids into 293T cells. Myc
14-3-3 was immunoprecipitated and coimmunoprecipitated. Flag-TAZ was probed with Flag antibody.
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explore the potential function of TAZ in oncogenes, we first
examined the effect of TAZ overexpression on cell prolifera-
tion. The normal immortalized human breast epithelial cell
line MCF10A was transduced with retroviruses expressing
TAZ or TAZ4SA mutants. Stable pools were established and
used for measuring cell proliferation. Both the MCF10A/TAZ
and MCF10A/TAZ4SA cells proliferated significantly faster
than the vector control cells (Fig. 4A). Furthermore, both the
MCF10A/TAZ and MCF10A/TAZ4SA cells continued prolif-
erating even after they reached confluence. To confirm this
result, we pulse-labeled different pools of cells with BrdU for
30 min and analyzed their cell cycle distribution by flow cytom-
etry. The parental MCF10A and vector control cells displayed
similar cell cycle distributions, with 8.16% and 8.19% BrdU-
positive cells, respectively. In contrast, the ectopic expression
of either TAZ or TAZ4SA dramatically increased the S-phase
cell population, in which 28.43% of MCF10A/TAZ cells and
46.05% MCF10A/TAZ4SA cells were BrdU positive, respec-
tively (Fig. 4B). Together, these data indicate that an increased
TAZ activity promotes cell proliferation and the cell prolifer-
ation activity of TAZ is negatively regulated by Mst2- and
Lats2-mediated phosphorylation.
TAZ promotes epithelial-mesenchymal transition. TAZ has
been reported previously to modulate mesenchymal stem cell
differentiation (9). We noticed that the TAZ-expressing cells,
especially the constitutively active TAZ4SA-expressing cells,
showed a dramatic alteration in cell morphology from that of
the vector control cells (Fig. 5A). MCF10A vector control cells
grew on monolayer cultures and displayed epithelium-type
glands. TAZ-transduced MCF10A cells, on the other hand,
showed an evident loss of epithelium-type characteristics. Both
TAZ4SA-transduced and TAZS89A-transduced MCF10A cells
displayed even stronger alterations in the morphology of spin-
dle shape (Fig. 5A). The morphological alterations were also
confirmed by phalloidin staining for F-actin, which is another
hallmark of EMT, indicating disorganization of adherens junc-
tions (22). The TAZ4SA-expressing cells displayed a dramatic
increase in stress fibers (Fig. 5B).
To test whether TAZ expression caused the EMT of MCF10A
cells, Western blotting was performed to examine the expression
of several well-characterized EMT markers. Epithelial markers
such as E-cadherin and occludin were down-regulated in
MCF10A/TAZ cells, and this downregulation was more dramatic
with TAZ4SA cells (Fig. 5C). Furthermore, the mesenchymal
markers N-cadherin, vimentin, and fibronectin were up-regulated
in TAZ-overexpressing MCF10A cells and to a higher level in
TAZ4SA cells (Fig. 5C). Together, these data indicate that TAZ
activation induces EMT in MCF10A cells.
To gain insight into the molecular mechanism underlying
TAZ-induced EMT, we next examined the mRNA levels of
E-cadherin and N-cadherin, markers for epithelial and mesen-
chymal cells, respectively. Quantitative reverse transcription
(RT)-PCR confirmed the Western blotting results indicating
that the expression of TAZ decreased E-cadherin expression
while increasing N-cadherin expression (Fig. 5D). We further
examined the mRNA levels of two transcription factors, Foxc2
and Snail, which have been shown to participate in EMT con-
trol. We found that the expression of TAZ, and to a stronger
degree, that of TAZ4SA, increased the levels of both Foxc2 and
Snail mRNA (Fig. 5D), indicating that TAZ regulates the
transcription program for EMT.
We then performed a wound-healing experiment to examine
the activity of TAZ and TAZ4SA mutants in promoting cell
migration and invasion. The motility of TAZ- and TAZ4SA-
FIG. 4. TAZ stimulates cell proliferation. (A) TAZ promotes cell growth. Growth curves of MCF10A cells stably expressing pBabe-vector,
-TAZ, and -TAZ4SA were determined. (B) TAZ increases the proliferation of MCF10A cells. A synchronized parental MCF10A and pBabe-vector,
-TAZ, and -TAZ4SA overexpressing MCF10A cells were labeled with BrdU (15 M for 30 min), followed by staining with anti-BrdU and propidium
iodide for flow cytometric analysis.
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expressing MCF10A cells was dramatically increased com-
pared with that of the parental MCF10A cells which exhibited
minimal, if any, wound closure (Fig. 6A). Finally, to further
examine the activity of TAZ in promoting cell migration and
invasion, we performed a 3D Matrigel assay. An equal number
of cells (5,000) were plated onto Matrigel, and acinar forma-
tion was followed at different times after cells were cultured
and examined microscopically. MCF10A/TAZ cells formed
FIG. 5. TAZ induces the EMT of MCF10A cells. (A) TAZ induces a morphology change in MCF10A cells. Phase-contrast images of MCF10A
cells expressing vector, TAZ, TAZS89A, and TAZ4SA are shown. WT, wild type. (B) TAZ alters the actin organization. Cells were stained with
rhodamine-conjugated phalloidin. (C) TAZ causes EMT in MCF10A cells. Cell lysates from MCF10A cells expressing vector, TAZ, and TAZ4SA
were separated and probed with antibodies for epithelial markers and mesenchymal markers as indicated. (D) TAZ decreases E-cadherin and
increases N-cadherin expression through the activation of EMT transcription. Total RNA was extracted from MCF10A-vector, -TAZ, and
-TAZ4SA cells, and quantitative PCR was performed to determine E-cadherin and N-cadherin expression (upper panel) and Foxc2 and Snail
expression (lower panel). All data are normalized to GAPDH.
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acini as early as 3 to 4 days, while visible acini were seen in
MCF10A control or MCF10A/pBabe cells only after 6 or 7
days (data not shown). At day 12, MCF10A/TAZ acini were
much larger than those of the the control (Fig. 6B). At this
stage, no acinus in either the MCF10A or the MCF10A/pBabe
plate was larger than 200 m in diameter, whereas more than
five acini in each chamber of the MCF10A/TAZ plate were
bigger than 300 m in diameter (Fig. 6B). Lumen formation
started to be seen in MCF10A/TAZ acini under phase-contrast
microscopy (Fig. 6, dark-colored centers are noted in the
MCF10A/TAZ acini). When acini were cultured further, at day
17, TAZ acini were bigger than 400 M and lumen were
observed clearly. Consistent with the previous result indicating
that increased TAZ activity promoted cell proliferation, the
mitotic index, as determined by the immunostaining of anti-
phospho-histone H3 (PH3), was low in the MCF10A/pBabe
control acini but was increased in the MCF10A/TAZ acini (day
17) (Fig. 6C). Collectively, these data show that TAZ promotes
the EMT of MCF10A cells, possibly by regulating the expres-
sion of key transcription factors involved in EMT.
DISCUSSION
The TAZ transcription coactivator has been implicated in
cell differentiation and organ development (10). The physio-
logical regulation of the TAZ protein is not clear. Our study
demonstrates that TAZ is regulated by the Hippo pathway,
which is a novel tumor suppressor pathway initially defined by
Drosophila genetic studies. Our data also indicate a role for
TAZ in cell proliferation and EMT.
During the course of this study, it was reported that YAP is
phosphorylated and inhibited by the Hippo pathway (6). TAZ
shares approximately 50% sequence identity with YAP. We
have determined that serine 89 in the HXRXXS motif is the
major Lats2 phosphorylation site in TAZ, while serine 311 is
also a functionally important site. Interestingly, the major Lats-
dependent phosphorylation site in TAZ (Ser89) identified in
this study corresponds to the major Lats-dependent phosphor-
ylation site in YAP (Ser127), reported by Dong et al. (6). We
also have supporting data indicating that YAP Ser127 is the
major Lats phosphorylation site.
Several lines of evidence support the phosphorylation of
TAZ by Lats2. First, TAZ contains four conserved HXRXXS
motifs, which likely represent the Lats recognition consensus.
Second, the coexpression of Lats2 induces a mobility shift of
TAZ, and this mobility shift can be completely reversed by
lambda phosphatase treatment. Third, Lats2 coexpression in-
creases the phosphorylation of TAZ Ser89, as indicated by
Western blotting with the phosphoYAP(Ser127) antibody.
Fourth, Lats2 directly phosphorylates TAZ in an in vitro ki-
nase assay. Fifth, a knockdown of endogenous Lats signifi-
cantly decreases TAZ Ser89 phosphorylation. Sixth, Lats2 pro-
motes cytoplasmic localization of the wild-type TAZ but not
the S89A mutant. Furthermore, the mutation of Ser89 or
Ser311 resulted in a TAZ mutant that is partially resistant to
inhibition by Lats2.
It has been reported that Akt/PKB was identified as a kinase
that phosphorylated YAP at its 14-3-3 binding site and inhib-
ited its transactivation function (1). However, the reported
YAP inhibition by Akt-dependent phosphorylation was incon-
sistent with the findings in our studies and those of Dong et al.
that Lats2 was responsible for YAP2 Ser127 phosphorylation
but not that of AKT (6, 38). This raises the question of whether
Akt also phosphorylates TAZ at its 14-3-3 binding site (Ser89).
Interestingly, Hong et al. have also reported that Akt does not
phosphorylate TAZ at its 14-3-3 binding site (Ser89) (10).
Therefore, we propose that TAZ is phosphorylated and inhib-
ited by Lats but not by AKT. Matallanas et al. have recently
reported that RASSF1A alleviated YAP1 cytoplasmic reten-
tion, thereby culminating in p73-mediated apoptosis, indicat-
ing that Yap1 might play a critical role in tumor suppression
FIG. 6. TAZ enhances cell migration and acinar growth in
MCF10A cells. (A) TAZ overexpression promotes cell migration.
MCF10A cells expressing vector, TAZ wild type (WT), and TAZ4SA
(4SA) were analyzed for migration by a wound-healing assay. (B) TAZ
stimulates acinar growth. MCF10A and derivative cells were cultured
in the Matrigel. The acini formed at day 12 and 17 are shown. Note the
large acini with lumen (L) formed by MCF-10A/TAZ. (C) TAZ pro-
motes MCF10A proliferation in Matrigel culture. MCF10A and de-
rivative cells were cultured in Matrigel and acini formed at day 17,
fixed, paraffin embedded, and immunostained with antibody to PH3.
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(18). These observations are inconsistent with the prevailing
model in which YAP functions as an oncogene and is inhibited
by the Hippo tumor suppressor pathway. Future studies are
required to fully understand the cellular function of YAP and
TAZ.
TAZ shares approximately 50% sequence identity with
YAP1 and YAP2, which are alternative splicing products of
the YAP gene. Both YAP and TAZ are phosphorylated and
inhibited by the Lats kinase. YAP controls organ size and has
been implicated in cancer development. Consistently we found
that TAZ also promotes cell growth. Furthermore, Yap has
been reported to induce EMT, while our study also indicates a
role for TAZ in promoting EMT. Therefore, YAP and TAZ
likely will have overlapping and distinct functions.
TAZ knockout mice have been independently reported by
two groups (9, 33). Hossain et al. showed that Wwtr1-null mice
have only minor skeletal defects but develop renal cysts (11),
and Makita et al. reported that TAZ inactivation in mice re-
sults in pathological changes in the kidney and lung, resem-
bling polycystic kidney disease and pulmonary emphysema,
respectively (17). Whether the TAZ knockout animals are
more resistant to tumor development has not been investi-
gated.
We propose a model of TAZ regulation by the Hippo path-
way via the following sequence. Lats phosphorylates TAZ on
Ser89. This phosphorylation creates a 14-3-3 binding site. The
phosphorylated TAZ then binds to 14-3-3 and is retained in
cytoplasm, resulting in the depletion of TAZ from the nucleus.
Therefore, TAZ fails to bind nuclear transcription factors and
cannot activate target genes when it is phosphorylated by Lats.
This model suggests that TAZ inactivation is an important
downstream signaling output of the Hippo pathway.
Our study indicates a function for TAZ in cell proliferation
and EMT, which are both important steps for cancer develop-
ment. The expression of TAZ in MCF10A cells significantly
increases the growth rate of the cells. Furthermore, the TAZ-
expressing cells continue to proliferate even when cells reach
confluence. This finding is supported by a high fraction of
TAZ-expressing cells that continue to synthesize DNA in a
confluent culture. Our study suggests the growth-stimulating
activity of TAZ.
Another interesting finding from this study is that TAZ
promotes EMT. The expression of TAZ, especially the phos-
phorylation-defective S89A and 4SA mutants, alters the mor-
phology of MCF10A cells. Moreover, the TAZ-expressing cells
showed a dramatic decrease in epithelial markers with a con-
comitant increase in mesenchymal markers. Therefore, TAZ
may play a role in cancer development by promoting prolifer-
ation and EMT. This notion is consistent with the fact that
TAZ is inhibited by the Hippo tumor suppressor pathway.
More interestingly, the expression of the TAZ phosphoryla-
tion-defective 4SA mutant not only significantly promotes cell
proliferation but also dramatically alters the morphology of
MCF10A cells, indicating that the functional role of TAZ in
cancer development may result from the dysregulation of the
Hippo pathway. Dysregulation of the upstream region of the
Hippo pathway such as NF2, Mst/Sav, and Lats/Mob would
lead to the inhibition of the Hippo pathway and subsequent
activation of TAZ by the loss of inhibitory phosphorylation.
Mer is a tumor suppressor, and Sav and Mob mutation have
also been reported in tumor cell lines (14, 31). Therefore, the
mutation or dysregulation of the components of the Hippo
pathway may result in promoting cell proliferation and induc-
ing EMT via activation of TAZ.
Studies of Drosophila have shown that the Hippo pathway
inhibits cell proliferation and induces apoptosis (12, 26). Dys-
regulation of the Hippo pathway results in organ and tissue
hypertrophy (7, 23, 26). Consistently, mutations of the tumor
suppressor NF2 gene coding for Mer provide direct evidence
supporting the tumor suppressor function of this pathway in
humans (19, 25, 35). Our discovery that TAZ promotes pro-
liferation and EMT provides a molecular basis for and addi-
tional support to the function of the Hippo pathway in tumor
suppression. We speculate that the phosphorylation and inac-
tivation of TAZ and YAP may represent the major down-
stream effects of the Hippo pathway in tumor suppression.
TAZ and YAP may be the key physiological substrates of Lats,
which is also a candidate of a tumor suppressor gene. In sum-
mary, our study has connected TAZ to the Hippo pathway and
suggests a potential function for TAZ in tumorigenesis.
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